Skip to main content
PMC home page
Gut logoLink to Gut
. 1979 Dec;20(12):1109–1124. doi: 10.1136/gut.20.12.1109

Corticosteroids in liver disease: possible mechanisms of action, pharmacology, and rational use.

A R Tanner, L W Powell
PMCID: PMC1412835  PMID: 393573

Full text

PDF
1109

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Atkinson J. P., Frank M. M. Effect of cortisone therapy on serum complement components. J Immunol. 1973 Oct;111(4):1061–1066. [PubMed] [Google Scholar]
  2. Atkinson J. P., Schreiber A. D., Frank M. M. Effects of corticosteroids and splenectomy on the immune clearance and destruction of erythrocytes. J Clin Invest. 1973 Jun;52(6):1509–1517. doi: 10.1172/JCI107325. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. BOGGS D. R., ATHENS J. W., CARTWRIGHT G. E., WINTROBE M. M. THE EFFECT OF ADRENAL GLUCOCORTICOSTEROIDS UPON THE CELLULAR COMPOSITION OF INFLAMMATORY EXUDATES. Am J Pathol. 1964 May;44:763–773. [PMC free article] [PubMed] [Google Scholar]
  4. Ballard P. L., Carter J. P., Graham B. S., Baxter J. D. A radioreceptor assay for evaluation of the plasma glucocorticoid activity of natural and synthetic steroids in man. J Clin Endocrinol Metab. 1975 Aug;41(2):290–304. doi: 10.1210/jcem-41-2-290. [DOI] [PubMed] [Google Scholar]
  5. Balow J. E., Hurley D. L., Fauci A. S. Immunosuppressive effects of glucocorticosteroids: differential effects of acute vs chronic administration on cell-mediated immunity. J Immunol. 1975 Mar;114(3):1072–1076. [PubMed] [Google Scholar]
  6. Balow J. E., Rosenthal A. S. Glucocorticoid suppression of macrophage migration inhibitory factor. J Exp Med. 1973 Apr 1;137(4):1031–1041. doi: 10.1084/jem.137.4.1031. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Baxter J. D., Forsham P. H. Tissue effects of glucocorticoids. Am J Med. 1972 Nov;53(5):573–589. doi: 10.1016/0002-9343(72)90154-4. [DOI] [PubMed] [Google Scholar]
  8. Baxter J. D., Rousseau G. G., Benson M. C., Garcea R. L., Ito J., Tomkins G. M. Role of DNA and specific cytoplasmic receptors in glucocorticoid action. Proc Natl Acad Sci U S A. 1972 Jul;69(7):1892–1896. doi: 10.1073/pnas.69.7.1892. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Becker M. D., Baptista A., Scheuer P. J., Sherlock S. Prognosis of chronic persistent hepatitis. Lancet. 1970 Jan 10;1(7637):53–57. doi: 10.1016/s0140-6736(70)91843-x. [DOI] [PubMed] [Google Scholar]
  10. Blitzer B. L., Mutchnick M. G., Joshi P. H., Phillips M. M., Fessel J. M., Conn H. O. Adrenocorticosteroid therapy in alcoholic hepatitis. A prospective, double-blind randomized study. Am J Dig Dis. 1977 Jun;22(6):477–484. doi: 10.1007/BF01072499. [DOI] [PubMed] [Google Scholar]
  11. Blum A. L., Stutz R., Haemmerli U. P., Schmid P., Grady G. F. A fortuitously controlled study of steroid therapy in acute viral hepatitis. I. Acute disease. Am J Med. 1969 Jul;47(1):82–92. doi: 10.1016/0002-9343(69)90243-5. [DOI] [PubMed] [Google Scholar]
  12. Brooks S. M., Werk E. E., Ackerman S. J., Sullivan I., Thrasher K. Adverse effects of phenobarbital on corticosteroid metabolism in patients with bronchial asthma. N Engl J Med. 1972 May 25;286(21):1125–1128. doi: 10.1056/NEJM197205252862103. [DOI] [PubMed] [Google Scholar]
  13. Buffington G. A., Dominguez J. H., Piering W. F., Hebert L. A., Kauffman H. M., Jr, Lemann J., Jr Interaction of rifampin and glucocorticoids. Adverse effect on renal allograft function. JAMA. 1976 Oct 25;236(17):1958–1960. [PubMed] [Google Scholar]
  14. Butler W. T. Corticosteroids and immunoglobulin synthesis. Transplant Proc. 1975 Mar;7(1):49–53. [PubMed] [Google Scholar]
  15. Campra J. L., Hamlin E. M., Jr, Kirshbaum R. J., Olivier M., Redeker A. G., Reynolds T. B. Prednisone therapy of acute alcoholic hepatitis. Report of a controlled trial. Ann Intern Med. 1973 Nov;79(5):625–631. doi: 10.7326/0003-4819-79-5-625. [DOI] [PubMed] [Google Scholar]
  16. Chadwick R. G., Galizzi J., Jr, Heathcote J., Lyssiotis T., Cohen B. J., Scheuer P. J., Sherlock S. Chronic persistent hepatitis: hepatitis B virus markers and histological follow-up. Gut. 1979 May;20(5):372–377. doi: 10.1136/gut.20.5.372. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Cochrane A. M., Moussouros A., Portmann B., McFarlane I. G., Thomson A. D., Eddleston, Williams R. Lymphocyte cytotoxicity for isolated hepatocytes in alcoholic liver disease. Gastroenterology. 1977 May;72(5 Pt 1):918–923. [PubMed] [Google Scholar]
  18. Conn H. O. Steroid treatment of alcoholic hepatitis. The yeas and the nays. Gastroenterology. 1978 Feb;74(2 Pt 1):319–322. [PubMed] [Google Scholar]
  19. Cook G. C., Mulligan R., Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med. 1971 Apr;40(158):159–185. doi: 10.1093/oxfordjournals.qjmed.a067264. [DOI] [PubMed] [Google Scholar]
  20. Cook J. A., DiLuzio N. R. Protective effect of cysteine and methylprednisolone in lead acetate-endotoxin induced shock. Exp Mol Pathol. 1973 Aug;19(1):127–138. doi: 10.1016/0014-4800(73)90046-4. [DOI] [PubMed] [Google Scholar]
  21. Craddock C. G., Winkelstein A., Matsuyuki Y., Lawrence J. S. The immune response to foreign red blood cells and the participation of short-lived lymphocytes. J Exp Med. 1967 Jun 1;125(6):1149–1172. doi: 10.1084/jem.125.6.1149. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Cutroneo K. R., Counts D. F. Anti-inflammatory steroids and collagen metabolism: glucocorticoid-mediated alterations of prolyl hydroxylase activity and collagen synthesis. Mol Pharmacol. 1975 Sep;11(5):632–639. [PubMed] [Google Scholar]
  23. Czaja A. J., Summerskill W. H. Chronic hepatitis. To treat or not to treat? Med Clin North Am. 1978 Jan;62(1):71–85. doi: 10.1016/s0025-7125(16)31823-5. [DOI] [PubMed] [Google Scholar]
  24. DERITIS F., GIUSTI G., MALLUCCI L., PIAZZA M. NEGATIVE RESULTS OF PREDNISONE THERAPY IN VIRAL HEPATITIS. Lancet. 1964 Mar 7;1(7332):533–534. doi: 10.1016/s0140-6736(64)92916-2. [DOI] [PubMed] [Google Scholar]
  25. DUCCI H., KATZ R. Cortisone, ACTH and antibiotics in fulminant hepatitis. Gastroenterology. 1952 Jul;21(3):357–374. [PubMed] [Google Scholar]
  26. Dale D. C., Fauci A. S., Guerry D I. V., Wolff S. M. Comparison of agents producing a neutrophilic leukocytosis in man. Hydrocortisone, prednisone, endotoxin, and etiocholanolone. J Clin Invest. 1975 Oct;56(4):808–813. doi: 10.1172/JCI108159. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Davis M., Williams R., Chakraborty J., English J., Marks V., Ideo G., Tempini S. Prednisone or prednisolone for the treatment of chronic active hepatitis? A comparison of plasma availability. Br J Clin Pharmacol. 1978 Jun;5(6):501–505. doi: 10.1111/j.1365-2125.1978.tb01664.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Dudley F. J., Fox R. A., Sherlock S. Cellular immunity and hepatitis-associated, Australia antigen liver disease. Lancet. 1972 Apr 1;1(7753):723–726. doi: 10.1016/s0140-6736(72)90234-6. [DOI] [PubMed] [Google Scholar]
  29. EVANS A. S., SPRINZ H., NELSON R. S. Adrenal hormone therapy in viral hepatitis. II. The effect of cortisone in the acute disease. Ann Intern Med. 1953 Jun;38(6):1134–1147. doi: 10.7326/0003-4819-38-6-1134. [DOI] [PubMed] [Google Scholar]
  30. Farrell G. C., Powell L. W. Chronic granulomatous hepatitis. Aust N Z J Med. 1976 Oct;6(5):474–478. doi: 10.1111/j.1445-5994.1976.tb03039.x. [DOI] [PubMed] [Google Scholar]
  31. Fauci A. S., Dale D. C. Alternate-day prednisone therapy and human lymphocyte subpopulations. J Clin Invest. 1975 Jan;55(1):22–32. doi: 10.1172/JCI107914. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Fauci A. S., Dale D. C., Balow J. E. Glucocorticosteroid therapy: mechanisms of action and clinical considerations. Ann Intern Med. 1976 Mar;84(3):304–315. doi: 10.7326/0003-4819-84-3-304. [DOI] [PubMed] [Google Scholar]
  33. Fauci A. S., Dale D. C. The effect of Hydrocortisone on the kinetics of normal human lymphocytes. Blood. 1975 Aug;46(2):235–243. [PubMed] [Google Scholar]
  34. Fauci A. S., Dale D. C. The effect of in vivo hydrocortisone on subpopulations of human lymphocytes. J Clin Invest. 1974 Jan;53(1):240–246. doi: 10.1172/JCI107544. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Fauci A. S. Mechanisms of corticosteroid action on lymphocyte subpopulations. II. Differential effects of in vivo hydrocortisone, prednisone and dexamethasone on in vitro expression of lymphocyte function. Clin Exp Immunol. 1976 Apr;24(1):54–62. [PMC free article] [PubMed] [Google Scholar]
  36. Ferluga J., Allison A. C. Role of mononuclear infiltrating cells in pathogenesis of hepatitis. Lancet. 1978 Sep 16;2(8090):610–611. doi: 10.1016/s0140-6736(78)92828-3. [DOI] [PubMed] [Google Scholar]
  37. GOLDGRABER M. B., KIRSNER J. B. The use of adrenal steroids in subacute and chronic cholangiolitic hepatitis; a clinicopathologic correlation. AMA Arch Intern Med. 1959 Mar;103(3):354–368. doi: 10.1001/archinte.1959.00270030010002. [DOI] [PubMed] [Google Scholar]
  38. GRANT L., PALMER P., SANDERS A. G. The effect of heparin on the sticking of white cells to endothelium in inflammation. J Pathol Bacteriol. 1962 Jan;83:127–133. [PubMed] [Google Scholar]
  39. Gregory P. B., Knauer C. M., Kempson R. L., Miller R. Steroid therapy in severe viral hepatitis. A double-blind, randomized trial of methyl-prednisolone versus placebo. N Engl J Med. 1976 Mar 25;294(13):681–687. doi: 10.1056/NEJM197603252941301. [DOI] [PubMed] [Google Scholar]
  40. HENCH P. S., KENDALL E. C., SLOCUMB C. H., POLLEY H. F. Effects of cortisone acetate and pituitary ACTH on rheumatoid arthritis, rheumatic fever and certain other conditions. Arch Intern Med (Chic) 1950 Apr;85(4):545–666. doi: 10.1001/archinte.1950.00230100002001. [DOI] [PubMed] [Google Scholar]
  41. HUBER T. E., WILEY A. T. Cortisone in the treatment of infectious hepatitis. Ann Intern Med. 1955 May;42(5):1011–1025. doi: 10.7326/0003-4819-42-5-1011. [DOI] [PubMed] [Google Scholar]
  42. Helman R. A., Temko M. H., Nye S. W., Fallon H. J. Alcoholic hepatitis. Natural history and evaluation of prednisolone therapy. Ann Intern Med. 1971 Mar;74(3):311–321. doi: 10.7326/0003-4819-74-3-311. [DOI] [PubMed] [Google Scholar]
  43. Israel H. L., Goldstein R. A. Hepatic granulomatosis and sarcoidosis. Ann Intern Med. 1973 Nov;79(5):669–678. doi: 10.7326/0003-4819-79-5-669. [DOI] [PubMed] [Google Scholar]
  44. KATZ R., VELASCO M., KLINGER J., ALESSANDRI H. Corticosteroids in the treatment of acute hepatitis in coma. Gastroenterology. 1962 Mar;42:258–265. [PubMed] [Google Scholar]
  45. Kozower M., Veatch L., Kaplan M. M. Decreased clearance of prednisolone, a factor in the development of corticosteroid side effects. J Clin Endocrinol Metab. 1974 Mar;38(3):407–412. doi: 10.1210/jcem-38-3-407. [DOI] [PubMed] [Google Scholar]
  46. LIPSCHUTZ E. W., CAPSON D. Cholangiolitic hepatitis, with special reference to its physiopathologic concept, diagnosis and therapy. Ann Intern Med. 1955 Nov;43(5):1037–1047. doi: 10.7326/0003-4819-43-5-1037. [DOI] [PubMed] [Google Scholar]
  47. Lesesne H. R., Bozymski E. M., Fallon H. J. Treatment of alcoholic hepatitis with encephalopathy. Comparison of prednisolone with caloric supplements. Gastroenterology. 1978 Feb;74(2 Pt 1):169–173. [PubMed] [Google Scholar]
  48. Lewis G. P., Jusko W. J., Graves L., Burke C. W. Prednisone side-effects and serum-protein levels. A collaborative study. Lancet. 1971 Oct 9;2(7728):778–780. doi: 10.1016/s0140-6736(71)92738-3. [DOI] [PubMed] [Google Scholar]
  49. Logsdon P. J., Middleton E., Jr, Coffey R. G. Stimulation of leukocyte adenyl cyclase by hydrocortisone and isoproterenol in asthmatic and nonasthmatic subjects. J Allergy Clin Immunol. 1972 Jul;50(1):45–56. doi: 10.1016/0091-6749(72)90078-4. [DOI] [PubMed] [Google Scholar]
  50. Long R. G., Meinhard E., Skinner R. K., Varghese Z., Wills M. R., Sherlock S. Clinical, biochemical, and histological studies of osteomalacia, osteoporosis, and parathyroid function in chronic liver disease. Gut. 1978 Feb;19(2):85–90. doi: 10.1136/gut.19.2.85. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Maddrey W. C., Boitnott J. K., Bedine M. S., Weber F. L., Jr, Mezey E., White R. I., Jr Corticosteroid therapy of alcoholic hepatitis. Gastroenterology. 1978 Aug;75(2):193–199. [PubMed] [Google Scholar]
  52. Meikle A. W., Clarke D. H., Tyler F. H. Cushing syndrome from low doses of dexamethasone. A result of slow plasma clearance. JAMA. 1976 Apr 12;235(15):1592–1593. [PubMed] [Google Scholar]
  53. Meikle A. W., Tyler F. H. Potency and duration of action of glucocorticoids. Effects of hydrocortisone, prednisone and dexamethasone on human pituitary-adrenal function. Am J Med. 1977 Aug;63(2):200–207. doi: 10.1016/0002-9343(77)90233-9. [DOI] [PubMed] [Google Scholar]
  54. Miller J., Smith M. G., Mitchell C. G., Reed W. D., Eddleston A. L., Williams R. Cell-mediated immunity to a human liver-specific antigen in patients with active chronic hepatitis and primary biliary cirrhosis. Lancet. 1972 Aug 12;2(7772):296–297. doi: 10.1016/s0140-6736(72)92904-2. [DOI] [PubMed] [Google Scholar]
  55. Mosley J. W., Combes B., Volwiler W., Zimmerman H. J. Letter: Corticosteroids in fulminant hepatitis. N Engl J Med. 1976 Oct 14;295(16):898–899. doi: 10.1056/nejm197610142951616. [DOI] [PubMed] [Google Scholar]
  56. Murray-Lyon I. M., Stern R. B., Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet. 1973 Apr 7;1(7806):735–737. doi: 10.1016/s0140-6736(73)92125-9. [DOI] [PubMed] [Google Scholar]
  57. Pardridge W. M., Mietus L. J. Transport of steroid hormones through the rat blood-brain barrier. Primary role of albumin-bound hormone. J Clin Invest. 1979 Jul;64(1):145–154. doi: 10.1172/JCI109433. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Parker C. W., Huber M. G., Baumann M. L. Alterations in cyclic AMP metabolism in human bronchial asthma. 3. Leukocyte and lymphocyte responses to steroids. J Clin Invest. 1973 Jun;52(6):1342–1348. doi: 10.1172/JCI107306. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Petereit L. B., Meikle A. W. Effectiveness of prednisolone during phenytoin therapy. Clin Pharmacol Ther. 1977 Dec;22(6):912–916. doi: 10.1002/cpt1977226912. [DOI] [PubMed] [Google Scholar]
  60. Plotz P. H. Editorial: Asymptomatic chronic hepatitis. Gastroenterology. 1975 Jun;68(6):1629–1630. [PubMed] [Google Scholar]
  61. Porter H. P., Simon F. R., Pope C. E., 2nd, Volwiler W., Fenster L. F. Corticosteroid therapy in severe alcoholic hepatitis. A double-blind drug trial. N Engl J Med. 1971 Jun 17;284(24):1350–1355. doi: 10.1056/NEJM197106172842404. [DOI] [PubMed] [Google Scholar]
  62. Powell L. W., Axelsen E. Corticosteroids in liver disease: studies on the biological conversion of prednisone to prednisolone and plasma protein binding. Gut. 1972 Sep;13(9):690–696. doi: 10.1136/gut.13.9.690. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Powell L. W., Tolman K. G. Treatment of inflammatory and metal storage diseases of the liver. Clin Gastroenterol. 1979 Jan;8(1):69–88. [PubMed] [Google Scholar]
  64. Redeker A. G., Schweitzer I. L., Yamahiro H. S. Letter: Randomization of corticosteroid therapy in fulminant hepatitis. N Engl J Med. 1976 Mar 25;294(13):728–729. doi: 10.1056/NEJM197603252941315. [DOI] [PubMed] [Google Scholar]
  65. Rinehart J. J., Balcerzak S. P., Sagone A. L., LoBuglio A. F. Effects of corticosteroids on human monocyte function. J Clin Invest. 1974 Dec;54(6):1337–1343. doi: 10.1172/JCI107880. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Rinehart J. J., Sagone A. L., Balcerzak S. P., Ackerman G. A., LoBuglio A. F. Effects of corticosteroid therapy on human monocyte function. N Engl J Med. 1975 Jan 30;292(5):236–241. doi: 10.1056/NEJM197501302920504. [DOI] [PubMed] [Google Scholar]
  67. Rousseau G. G., Baxter J. D., Tomkins G. M. Glucocorticoid receptors: relations between steroid binding and biological effects. J Mol Biol. 1972 Jun 14;67(1):99–115. doi: 10.1016/0022-2836(72)90389-0. [DOI] [PubMed] [Google Scholar]
  68. Rueff B., Benhamou J. P. Acute hepatic necrosis and fulminant hepatic failure. Gut. 1973 Oct;14(10):805–815. doi: 10.1136/gut.14.10.805. [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. SCHAYER R. W. Induced synthesis of histamine, microcirculatory regulation and the mechanism of action of the adrenal glucocorticoid hormones. Prog Allergy. 1963;7:187–212. [PubMed] [Google Scholar]
  70. SHALDON S., SHERLOCK S. Virus hepatitis with features of prolonged bile retention. Br Med J. 1957 Sep 28;2(5047):734–738. doi: 10.1136/bmj.2.5047.734. [DOI] [PMC free article] [PubMed] [Google Scholar]
  71. Schalm S. W., Summerskill W. H., Go V. L. Prednisone for chronic active liver disease: pharmacokinetics, including conversion to prednisolone. Gastroenterology. 1977 May;72(5 Pt 1):910–913. [PubMed] [Google Scholar]
  72. Schreiber A. D., Parsons J., McDermott P., Cooper R. A. Effect of corticosteroids on the human monocyte IgG and complement receptors. J Clin Invest. 1975 Nov;56(5):1189–1197. doi: 10.1172/JCI108196. [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Sherlock S., Datta D. V., Walker J. G. Prognosis and treatment of primary biliary cirrhosis. Rev Int Hepatol. 1966;16(2):217–225. [PubMed] [Google Scholar]
  74. Simon H. B., Wolff S. M. Granulomatous hepatitis and prolonged fever of unknown origin: a study of 13 patients. Medicine (Baltimore) 1973 Jan;52(1):1–21. doi: 10.1097/00005792-197301000-00001. [DOI] [PubMed] [Google Scholar]
  75. Smith C. I., Cooksley W. G., Powell L. W. Immunological abnormalities associated with liver disease: cause or effect? Aust N Z J Med. 1977 Dec;7(6):604–612. doi: 10.1111/j.1445-5994.1977.tb02316.x. [DOI] [PubMed] [Google Scholar]
  76. Smith M. G., Golding P. L., Eddleston A. L., Mitchell C. G., Kemp A., Williams R. Cell-mediated immune responses in chronic liver diseases. Br Med J. 1972 Feb 26;1(5799):527–530. doi: 10.1136/bmj.1.5799.527. [DOI] [PMC free article] [PubMed] [Google Scholar]
  77. Snyder N., Bessoff J., Dwyer J. M., Conn H. O. Depressed delayed cutaneous hypersensitivity in alcoholic hepatitis. Am J Dig Dis. 1978 Apr;23(4):353–358. doi: 10.1007/BF01072420. [DOI] [PubMed] [Google Scholar]
  78. Soloway R. D., Summerskill W. H., Baggenstoss A. H., Geall M. G., Gitnićk G. L., Elveback I. R., Schoenfield L. J. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology. 1972 Nov;63(5):820–833. [PubMed] [Google Scholar]
  79. Stavy L., Cohen I. R., Feldman M. The effect of hydrocortisone on lymphocyte-mediated cytolysis. Cell Immunol. 1973 May;7(2):302–312. doi: 10.1016/0008-8749(73)90252-9. [DOI] [PubMed] [Google Scholar]
  80. Suddick R. P. Glucocorticoid-kinin antagonism in the rat. Am J Physiol. 1966 Sep;211(3):844–850. doi: 10.1152/ajplegacy.1966.211.3.844. [DOI] [PubMed] [Google Scholar]
  81. Summerskill W. H. Chronic active liver disease reexamined: prognosis hopeful. Gastroenterology. 1974 Mar;66(3):450–464. [PubMed] [Google Scholar]
  82. Summerskill W. H., Korman M. G., Ammon H. V., Baggenstoss A. H. Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut. 1975 Nov;16(11):876–883. doi: 10.1136/gut.16.11.876. [DOI] [PMC free article] [PubMed] [Google Scholar]
  83. Tanner A. R., Caffin J. A., Halliday J. W., Powell L. W. Concurrent administration of antacids and prednisone: effect on serum levels of prednisolone. Br J Clin Pharmacol. 1979 Apr;7(4):397–400. doi: 10.1111/j.1365-2125.1979.tb00952.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  84. Thompson E. B., Lippman M. E. Mechanism of action of glucocorticoids. Metabolism. 1974 Feb;23(2):159–202. doi: 10.1016/0026-0495(74)90113-9. [DOI] [PubMed] [Google Scholar]
  85. WEISSMANN G., THOMAS L. Studies on lysosomes. II. The effect of cortisone on the release of acid hydrolases from a large granule fraction of rabbit liver induced by an excess of vitamin A. J Clin Invest. 1963 May;42:661–669. doi: 10.1172/JCI104757. [DOI] [PMC free article] [PubMed] [Google Scholar]
  86. Wahl S. M., Altman L. C., Rosenstreich D. L. Inhibition of in vitro lymphokine synthesis by glucocorticosteroids. J Immunol. 1975 Aug;115(2):476–481. [PubMed] [Google Scholar]
  87. Ward P. A. The chemosuppression of chemotaxis. J Exp Med. 1966 Aug 1;124(2):209–226. doi: 10.1084/jem.124.2.209. [DOI] [PMC free article] [PubMed] [Google Scholar]
  88. Ware A. J., Jones R. E., Shorey J. W., Combes B. A controlled trial of steroid therapy in massive hepatic necrosis. Am J Gastroenterol. 1974 Aug;62(2):130–133. [PubMed] [Google Scholar]
  89. Webel M. L., Ritts R. E., Jr, Taswell H. F., Danadio J. V., Jr, Woods J. E. Cellular immunity after intravenous administration of methylprednisolone. J Lab Clin Med. 1974 Mar;83(3):383–392. [PubMed] [Google Scholar]
  90. Weiersmüller A., Colombo J. P., Bircher J. The influence of prednisolone on hepatic function in normal subjects. Effects on galactose elimination capacity, sulfobromophthalein transport maximum and storage capacity, and D-glucaric acid output. Am J Dig Dis. 1977 May;22(5):424–428. doi: 10.1007/BF01071890. [DOI] [PubMed] [Google Scholar]
  91. Werdelin O., McCluskey R. T. The nature and the specificity of mononuclear cells in experimental autoimmune inflammations and the mechanisms leading to their accumulation. J Exp Med. 1971 Jun 1;133(6):1242–1263. doi: 10.1084/jem.133.6.1242. [DOI] [PMC free article] [PubMed] [Google Scholar]
  92. Weston W. L., Claman H. N., Krueger G. G. Site of action of cortisol in cellular immunity. J Immunol. 1973 Mar;110(3):880–883. [PubMed] [Google Scholar]
  93. Wright E. C., Seeff L. B., Berk P. D., Jones A., Plotz P. H. Treatment of chronic active hepatitis. An analysis of three controlled trials. Gastroenterology. 1977 Dec;73(6):1422–1430. [PubMed] [Google Scholar]
  94. Yu D. T., Clements P. J., Paulus H. E., Peter J. B., Levy J., Barnett E. V. Human lymphocyte subpopulations. Effect of corticosteroids. J Clin Invest. 1974 Feb;53(2):565–571. doi: 10.1172/JCI107591. [DOI] [PMC free article] [PubMed] [Google Scholar]
  95. ZWEIFACH B. W., SHORR E., BLACK M. M. The influence of the adrenal cortex on behavior of terminal vascular bed. Ann N Y Acad Sci. 1953 Jul 17;56(4):626–633. doi: 10.1111/j.1749-6632.1953.tb27383.x. [DOI] [PubMed] [Google Scholar]
  96. Zetterman R. K., Luisada-Opper A., Leevy C. M. Alcoholic hepatitis. Cell-mediated immunological response to alcoholic hyalin. Gastroenterology. 1976 Mar;70(3):382–384. [PubMed] [Google Scholar]
  97. von Meyer zum Büschenfelde K. H., Knolle J., Berger J. Celluläre Immunreaktionen gegenüber homologen leberspezifischen Antigenen (HLP) bei chronischen Leberentzündungen. Klin Wochenschr. 1974 Mar 1;52(5):246–248. doi: 10.1007/BF01468598. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES